Novo Nordisk A/S: US Supreme Court ruling allows Caraco Pharmaceutical to challenge Novo Nordisk's patent submissions for Prandin® (repaglinide)
2012-04-17 · Novo Nordisk A/S · original novonordisk.com ↗
Today, Novo Nordisk announced that the US Supreme Court has reversed the US Court of Appeals for the Federal Circuit's April 2010 decision. That decision dismissed generic manufacturer Caraco Pharmaceutical's claim to change Novo Nordisk's patent submissions regarding the combination use of repaglinide and metformin for the treatment of type 2 diabetes. Further information: Media: Investors: Mike Rulis Klaus Bülow Davidsen Tel: (+45) 3079 3573 Tel: (+45) 4442 3176 [email protected] [email protected] Frank Daniel Mersebach Tel: (+45) 4442 0604 [email protected] Lars Borup Jacobsen Tel: (+45) 3075 3479 [email protected] In North America: Ken Inchausti Jannick Lindegaard Tel: (+1) 609 514 8316 Tel: (+1) 609 786 4575 [email protected] [email protected] Company Announcement No 25 / 2012
The release as fetched from its publisher. novonordisk.com ↗